Financial Performance - The company reported a revenue of 1.2 billion CNY for the fiscal year 2024, representing a year-over-year growth of 15%[23]. - The company's operating revenue for 2024 reached ¥1,943,387,830, representing a 32.42% increase compared to ¥1,467,569,910 in 2023[29]. - Net profit attributable to shareholders for 2024 was ¥338,061,776, marking a 40.84% increase from ¥240,036,047 in 2023[29]. - The total profit for 2024 was CNY 395,031,285.42, reflecting a growth of 49.07% compared to the previous year[53]. - The company achieved significant improvements in production management, enhancing operational efficiency and achieving smart factory foundations through resource optimization and equipment upgrades[54]. - The company reported a total revenue of 372.4 million in the latest fiscal year, reflecting a year-over-year increase of 106.4%[137]. - The company plans to distribute equity dividends amounting to 220.6 million, which represents a 40% increase compared to the previous year[138]. Research and Development - The company aims to expand its research and development investments to address intensified market competition and broaden its ophthalmic product line[6]. - The company is focused on improving its R&D capabilities and managing risks associated with new drug development, which has long cycles and unpredictable factors[8]. - The company is investing 200 million CNY in R&D for new technologies and product development in the ophthalmology sector[23]. - The company has strengthened its R&D capabilities by collaborating with domestic and international research institutions, focusing on innovative drug development[58]. - Research and development investment for the reporting period was 235 million yuan, resulting in 17 new invention patents[121]. - The company is in the clinical research phase for several new drug projects aimed at treating eye diseases, which are expected to enhance market competitiveness[85]. Market Expansion and Strategy - The company recognizes the potential risks from increased competition and plans to explore new markets to maintain its growth trajectory[5]. - Market expansion plans include entering three new provinces in China by the end of 2024, targeting a 10% market share in these regions[23]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of 300 million CNY allocated for this purpose[23]. - The company is committed to expanding its market presence and enhancing its product pipeline through strategic initiatives and new product launches[62]. - The company is focusing on expanding its market presence, particularly in the healthcare sector, with plans to enhance product offerings and technological advancements[140]. Product Development and Launches - New product launches include the "兴齐美欧品" and "兹润" eye drops, which are expected to contribute significantly to revenue in the upcoming quarters[23]. - The company launched "Atropine Sulfate Eye Drops" in March 2024, which is the first product of its kind for myopia treatment in the domestic market[40]. - The company has developed a comprehensive product pipeline covering common eye diseases, with several key products recommended by 62 authoritative guidelines[64]. - The product "Zhi Run® Cyclosporine Eye Drops (II)" has been included in 16 clinical guidelines and has received multiple awards for its excellence in the ophthalmic field[40]. Operational Efficiency and Cost Management - The company is taking measures to mitigate rising raw material costs by developing new suppliers and managing energy consumption[9]. - The company aims to improve its production capacity by 40% by upgrading its facilities to meet increasing demand[23]. - The company achieved significant improvements in production management, enhancing operational efficiency and achieving smart factory foundations through resource optimization and equipment upgrades[54]. - The company is committed to continuous improvement in R&D efficiency and innovation in drug formulations, aiming for global competitiveness[70]. Corporate Governance and Compliance - The company has a well-defined corporate governance structure, with a shareholders' meeting as the highest authority, a board of directors for decision-making, and a supervisory board for oversight, ensuring independence from controlling shareholders[132]. - The company has established a strict internal control management system covering key areas such as decision-making, asset management, and financial reporting[125]. - The company actively engages with stakeholders to balance interests and fulfill social responsibilities[127]. - The company has implemented a transparent performance evaluation and incentive mechanism for senior management[126]. Environmental Responsibility - The company has applied for a pollution discharge permit valid from July 28, 2023, to July 27, 2028, issued by the Shenyang Ecological Environment Bureau[196]. - The wastewater treatment plant has been upgraded in 2023, increasing the daily processing capacity to 480 m³/day, utilizing A2O+MBR technology[198]. - The company is committed to compliance with environmental regulations and standards in its waste management practices[199]. - The company has received approvals for multiple environmental impact assessments related to new projects, including the R&D center and packaging workshop[196]. Talent Development and Human Resources - The company emphasizes talent development, ensuring a strong team with rich experience and complementary skills[74]. - The company has established a comprehensive training system, integrating long-term education with internal and external training[165]. - The educational background of employees shows that 199 hold a master's degree or above, while 1,268 have a bachelor's degree, reflecting a well-educated workforce[162]. - The company has a structured remuneration scheme based on the responsibilities of the positions held by the directors and senior management[148].

Group 1 - The vitamin sector experienced a decline of 1.97% on April 16, with a net outflow of 183 million yuan from main funds, where 4 stocks rose and 26 stocks fell [1] - The companies with the highest net outflow of main funds included China Resources Sanjiu (588.49 million yuan), Xingqi Eye Medicine (313.44 million yuan), Shengda Biology (188.84 million yuan), North China Pharmaceutical (183.74 million yuan), and Nengte Technology (181.81 million yuan) [1] Group 2 - The top stock by net inflow was Huayuan Biological, with a net inflow of 32.28 million yuan and a price increase of 0.29% [2] - New Hec (21.80 yuan) saw a decline of 1.71% with a net inflow of 16.02 million yuan, while Brother Technology (4.02 yuan) experienced a significant drop of 6.07% with a net inflow of 9.80 million yuan [2] - Other notable declines included Zhejiang Medicine (-1.23%), Hendi Pharmaceutical (-1.37%), and Weixin Kang (-1.80%), all showing negative net inflows [2]

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于近日收到由辽宁省科学 技术厅、辽宁省财政厅、国家税务总局辽宁省税务局联合颁发的《高新技术企业 证书》，证书编号为：GR202421000348，发证时间为 2024 年 11 月 27 日，有效期 为三年。 公司本次高新技术企业的认定系原《高新技术企业证书》有效期满后进行的 重新认定。根据《中华人民共和国企业所得税法》以及国家对高新技术企业的相 关税收规定，公司自通过高新技术企业重新认定后，可连续三年(2024 年-2026 年)继续享受高新技术企业的税收优惠政策，按 15%的税率缴纳企业所得税。 公司 2024 年已根据相关规定按 15%的企业所得税税率进行纳税申报及预缴， 因此，本次通过高新技术企业重新认定不会对公司 2024 年度经营业绩产生影响。 特此公告。 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-003 沈阳兴齐眼药股份有限公司 关于公司通过高新技术企业重新认定的公告 沈阳兴齐眼药股份有限公司 董事会 2025 年 4 月 8 日 ...

Core Viewpoint - The recent performance of Zhaoke Ophthalmology shows significant revenue growth and a narrowing net loss, while investors are particularly interested in the approval timeline for its key product, low-concentration atropine eye drops [1][4]. Financial Performance - Zhaoke Ophthalmology reported a revenue of 69.32 million HKD for 2024, representing a year-on-year increase of 268.6% [1]. - The company's net loss decreased by 38.3% compared to the previous year [1]. - Cash reserves reached 1.12 billion HKD [1]. Product Approval and Market Potential - Zhaoke Ophthalmology's low-concentration atropine eye drops (NVK002) have been accepted for a simplified new drug application by the National Medical Products Administration [1]. - The target patient group for NVK002 includes children and adolescents aged 3 to 17 [1]. - The market demand for atropine eye drops is believed to be larger than that for PD-1 treatments, indicating significant growth potential [5]. Competitive Landscape - Currently, the only approved low-concentration atropine eye drops are held by Xingqi Eye Medicine, which has faced challenges in meeting sales expectations [2][3]. - Xingqi Eye Medicine's total revenue from eye drops, including atropine, was reported at 512 million CNY, suggesting that the sales of atropine may not reach the previously forecasted 1.5 billion CNY [3]. - Zhaoke Ophthalmology is preparing to scale operations rapidly upon the approval of NVK002, indicating a proactive approach to market entry [5]. Future Outlook - Zhaoke Ophthalmology is targeting three major indications: childhood myopia, dry eye syndrome, and wet age-related macular degeneration, with several products expected to enter the market within the next 1 to 2 years [5].

资金流向方面，今日主力资金净流入8285.63万元，占比成交额9.71%。其中，超大单净流入1377.28万 元、占成交额1.61%，大单净流入6908.36万元、占成交额8.1%，中单净流出流入2085.62万元、占成交 额2.44%，小单净流出10371.25万元、占成交额12.15%。 兴齐眼药（300573）3月24日主力资金净流入 8285.63万元 金融界消息 截至2025年3月24日收盘，兴齐眼药（300573）报收于80.17元，上涨2.73%，换手率8.0%， 成交量10.78万手，成交金额8.53亿元。 天眼查商业履历信息显示，沈阳兴齐眼药股份有限公司，成立于1977年，位于沈阳市，是一家以从事医 药制造业为主的企业。企业注册资本12458.9194万人民币，实缴资本243万人民币。公司法定代表人为 刘继东。 通过天眼查大数据分析，沈阳兴齐眼药股份有限公司共对外投资了9家企业，参与招投标项目3069次， 知识产权方面有商标信息492条，专利信息153条，此外企业还拥有行政许可204个。 来源：金融界 兴齐眼药最新一期业绩显示，截至2024三季报，公司营业总收入14.39亿元、同比增长30. ...

近日，中国工业和信息化部办公厅公布2024年度绿色制造名单，兴齐眼药凭借在绿色制造领域的优秀表 现荣获国家级"绿色工厂"称号。这一荣誉不仅是对兴齐眼药践行绿色发展理念的肯定，更标志着公司在 推动可持续发展、构建绿色制造体系方面迈上了新台阶。 国家绿色制造名单评选活动由工业和信息化部组织开展，旨在推动工业绿色发展，提高资源利用效率， 构建和完善绿色制造与服务体系。其中，国家绿色工厂作为绿色制造核心实施单元，是指实现用地集约 化、原料无害化、生产洁净化、废物资源化、能源低碳化的企业。 国家绿色工厂的评选标准由《绿色工厂评价通则》和114项行业性评价要求组成，涉及绿色生产、绿色 管理、绿色技术、绿色产品等多个专业测评方面，旨在树立行业标杆，引领工业领域向绿色低碳转型。 多年来，兴齐眼药以可持续发展为导向，积极践行ESG理念，推进相关工作全面开展，在追求企业发展 的同时，兼顾环境、社会和公司治理责任，为利益相关方创造长远价值。未来，兴齐眼药将持续提升绿 色制造水平，探索绿色发展路径，为社会可持续发展贡献力量。（燕云） 校对：苏焕文 ...

Group 1: Company Overview - Shenyang Xingqi Eye Pharmaceutical Co., Ltd. is recognized for its high-quality party organization leading to high-quality corporate development, receiving honors such as "Liaoning Province Advanced Grassroots Party Organization" [2] - The company has established a comprehensive ophthalmic drug product system, covering ten categories and producing various forms including gels, eye drops, and ointments [3] Group 2: Product and Technology - The company holds 59 approved ophthalmic drug numbers, with 37 products included in the medical insurance directory and 6 in the national essential drug list [3] - The R&D center has seven technology platforms and various functional departments covering all stages of ophthalmic drug development, recognized as a high-tech enterprise [3] Group 3: Research and Development - The R&D team consists of professionals from top universities, with over 83% holding degrees in pharmacy-related fields and nearly 46% holding master's or doctoral degrees [3] - The company has been designated as a national enterprise technology center and has established a national postdoctoral research station [3] Group 4: Recent Developments - The company’s "China Pharmaceutical Packaging Eye Preparation Research Center" was approved on June 17, 2024, aimed at promoting innovation and technological progress in the pharmaceutical packaging industry [3]

本次公司共有 37 个产品继续纳入国家医保目录，其中甲类 8 个，乙类 29 个。 环孢素滴眼液(Ⅱ)、复方电解质眼内冲洗液、玻璃酸钠滴眼液等多种产品继续纳 入《国家医保目录》；本次公司没有产品退出《国家医保目录》。 证券代码：300573 证券简称：兴齐眼药 公告编号：2024-062 沈阳兴齐眼药股份有限公司 关于公司产品继续纳入医保目录的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2024年11月28日，国家医保局、人力资源社会保障部发布了《关于印发<国 家基本医疗保险、工伤保险和生育保险药品目录（2024年）>的通知》（医保发 〔2024〕33号），沈阳兴齐眼药股份有限公司（以下简称"公司"）产品纳入《国 家医保药品目录》的有关情况如下： 一、纳入《医保目录》的基本情况 二、《医保目录》信息调整的情况 本次《医保目录》调整了部分产品的医保支付标准，详情如下： | 药品 | 药品分 | 国家医保 分类（甲 | 医保支付标准 | | 协议有效期 | | --- | --- | --- | --- | --- | --- | | 名称 | 类代码 ...

1 证券代码：300573 证券简称：兴齐眼药 沈阳兴齐眼药股份有限公司 投资者关系活动记录表 编号：2024-006 | --- | --- | --- | --- | --- | --- | |--------------------------|----------------------------------------------|-------------|----------------------------------------------------------------|-------|-------------------------| | | | | | | | | | √ 特定对象调研 □ | | 分析师会议 | | | | 投资者关系 | □ 媒体采访 □ | | 业绩说明会 | | | | 活动类别 | □ 新闻发布会 | □ | 路演活动 | | | | | □现场参观 □ | | 其他（电话会议） | | | | 参与单位名称 及人员姓名 | 德邦证券 吴明华、富国基金 国海富兰克林基金 | | 赵伟、信达澳亚 刘牧、前海开源基金 于成龙。 | | 刘颢然、永赢基金 ...

证券代码：300573 证券简称：兴齐眼药 公告编号：2024-061 沈阳兴齐眼药股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于2024年4月17日召开第五 届董事会第二次会议、第五届监事会第二次会议，分别审议通过了《关于续聘2024 年度审计机构的议案》，同意续聘立信会计师事务所（特殊普通合伙）（以下简称 "立信"）为公司2024年度审计机构，聘用期限为一年，具体内容详见公司于2024 年4月19日在巨潮资讯网（www.cninfo.com.cn）披露的《关于续聘2024年度审计 机构的公告》（公告编号：2024-018）。2024年5月13日，公司召开2023年度股东 大会审议通过该议案。 近日，公司收到立信出具的《关于变更签字注册会计师的说明》，现将具体 情况公告如下： 一、本次变更签字注册会计师情况 立信为公司2024年度财务报表审计机构，原委派冯蕾女士、戴文捷女士为公 司2024年度财务报表审计报告的签字注册会计师。鉴于戴文捷女士工作安排调 整，现委派程人坚 ...